CTMX
HealthcareCytomX Therapeutics, Inc.
$4.12
$-0.13 (-3.06%)
Jan 5, 2026
Price History (1Y)
Analysis
CytomX Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $698.07 million and 119 employees. Its revenue over the trailing twelve months (TTM) totals $113.63 million. The company's financial health indicates significant profitability, with a gross margin of 100.0% and net income of $28.02 million over the TTM. Return on Equity stands at 66.8%, while return on assets is 9.8%. The balance sheet shows $143.63 million in cash and debt totaling $5.60 million, resulting in a debt-to-equity ratio of 5.21. The company's valuation context features a P/E ratio (TTM) of 13.73 and an operating margin of -264.4%, which may indicate challenges in generating earnings from revenue. Revenue growth over the past year has been -82.2%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $698.07M
- P/E Ratio
- 13.73
- 52-Week High
- $4.66
- 52-Week Low
- $0.40
- Avg Volume
- 3.08M
- Beta
- 2.42
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 119